Technical Analysis for URGN - UroGen Pharma Ltd.

Grade Last Price % Change Price Change
grade F 40.4 -1.66% -0.68
URGN closed down 1.66 percent on Tuesday, February 19, 2019, on 33 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical URGN trend table...

Date Alert Name Type % Chg
Feb 19 180 Bearish Setup Bearish Swing Setup 0.00%
Feb 15 MACD Bullish Signal Line Cross Bullish -1.66%
Feb 15 Narrow Range Bar Range Contraction -1.66%
Feb 15 Wide Bands Range Expansion -1.66%
Feb 14 Multiple of Ten Bullish Other -0.35%
Feb 14 Wide Bands Range Expansion -0.35%
Feb 13 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.27%
Feb 13 Wide Bands Range Expansion -0.27%
Feb 12 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.05%
Feb 12 Narrow Range Bar Range Contraction -1.05%

Older signals for URGN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Medicine Biopharmaceutical Cancer Surgery Chemotherapy Antineoplastic Drugs Overactive Bladder Non Muscle Invasive Bladder Cancer Interstitial Cystitis
Is URGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 69.57
52 Week Low 36.95
Average Volume 212,625
200-Day Moving Average 48.1532
50-Day Moving Average 45.088
20-Day Moving Average 41.8405
10-Day Moving Average 40.651
Average True Range 1.9856
ADX 29.79
+DI 14.3644
-DI 25.178
Chandelier Exit (Long, 3 ATRs ) 49.1732
Chandelier Exit (Short, 3 ATRs ) 44.4968
Upper Bollinger Band 47.8445
Lower Bollinger Band 35.8365
Percent B (%b) 0.38
BandWidth 28.699466
MACD Line -1.6403
MACD Signal Line -1.696
MACD Histogram 0.0557
Fundamentals Value
Market Cap 525.57 Million
Num Shares 13 Million
EPS -1.67
Price-to-Earnings (P/E) Ratio -24.19
Price-to-Sales 20.42
Price-to-Book 4.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 42.76
Resistance 3 (R3) 42.96 42.37 42.36
Resistance 2 (R2) 42.37 41.77 42.27 42.23
Resistance 1 (R1) 41.39 41.40 41.10 41.19 42.10
Pivot Point 40.80 40.80 40.66 40.70 40.80
Support 1 (S1) 39.82 40.20 39.53 39.62 38.70
Support 2 (S2) 39.23 39.83 39.13 38.57
Support 3 (S3) 38.25 39.23 38.44
Support 4 (S4) 38.05